Advertisement
Advertisement
CPRX
Catalyst Pharmaceutical Inc.
24.40
USDSponsored
-0.37
-1.51%
Mar 11, 15:59 UTC -4
Closed
After-Market
24.46
+0.06
+0.25%
CPRX Earnings Reports
Positive Surprise Ratio
CPRX beat 30 of 41 last estimates.
73%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$150.03M
/$0.45
Implied change from Q4 25 (Revenue/ EPS)
-1.69%
/+9.76%
Implied change from Q1 25 (Revenue/ EPS)
+6.09%
/--
Catalyst Pharmaceutical Inc. earnings per share and revenue
On Feb 25, 2026, CPRX reported earnings of 0.41 USD per share (EPS) for Q4 25, beating the estimate of 0.34 USD, resulting in a 19.64% surprise. Revenue reached 152.61 million, compared to an expected 144.87 million, with a 5.34% difference. The market reacted with a +0.08% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.45 USD, with revenue projected to reach 150.03 million USD, implying an increase of 9.76% EPS, and decrease of -1.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Guardian Pharmacy Services, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.25
Actual
$0.37
Surprise
+45.10%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.45
Actual
-$0.42
Surprise
+6.77%
Esperion Therapeutics, Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.24
Actual
$0.22
Surprise
-10.46%
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
Zevra Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
$0.05
Actual
$0.21
Surprise
+311.76%
SIGA Technologies Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
-Actual
-$0.08
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.19
Actual
$0.30
Surprise
+54.80%
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.51
Surprise
+37.05%
FAQ
What were Catalyst Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Catalyst Pharmaceutical Inc. reported EPS of $0.41, beating estimates by 19.64%, and revenue of $152.61M, 5.34% above expectations.
How did the market react to Catalyst Pharmaceutical Inc.'s Q4 2025 earnings?
The stock price moved up 0.08%, changed from $24.86 before the earnings release to $24.88 the day after.
When is Catalyst Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Catalyst Pharmaceutical Inc.'s next earnings report?
Based on 5
analysts, Catalyst Pharmaceutical Inc. is expected to report EPS of $0.45 and revenue of $150.03M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement